Creative Planning Galectin Therapeutics Inc Transaction History

Creative Planning

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$1.6 - $2.18 $6,400 - $8,720	4,000 Added 19.79%	24,214 $40,000
Q3 2023 Nov 16, 2023	SELL	$1.38 - $1.97 $1,150 - $1,642	-834 Reduced 3.96%	20,214 $38,000
Q1 2022 May 16, 2022	BUY	$1.61 - $2.31 $16,100 - $23,100	10,000 Added 90.51%	21,048 $34,000
Q4 2021 Feb 11, 2022	BUY	$2.07 - $3.8 $22,869 - $41,982	11,048 New	11,048 $23,000

9.65M

1.16M

1.98M

Ticker GALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,426,000
Market Cap $123M
Description
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial f...

Get notified when there are updates to the investment portfolio of Creative Planning, based on Form 13F filings with the SEC.

Stay updated on Creative Planning with notifications on news.